What is STRM.BIO?
STRM.BIO operates at the forefront of the biotechnology sector, specializing in the engineering of extracellular vesicles to serve as efficient, non-viral delivery vehicles for genetic medicine. Unlike conventional methods that often face limitations regarding immunogenicity and manufacturing scalability, STRM.BIO's approach leverages the natural biological properties of EVs to transport therapeutic payloads directly to target tissues. This methodology is designed to enhance the safety profile of gene therapies, making them more practical for widespread clinical application. By addressing the fundamental challenges of therapeutic delivery, the company is carving out a distinct niche within the competitive landscape of rare disease treatment, supported by a leadership team dedicated to translating complex science into scalable, patient-centric solutions.
How much funding has STRM.BIO raised?
STRM.BIO has raised a total of $8M across 1 funding round:
Seed
$8M
Seed (2026): $8M with participation from BlueBay Asset Management, Boehringer Ingelheim Venture Fund, Delos Capital, and RECORDATI
Key Investors in STRM.BIO
Boehringer Ingelheim Venture Fund
A venture arm of a global pharmaceutical leader that invests in pioneering science and first-in-class, disease-modifying therapeutics across various modalities.
Delos Capital
A specialized venture capital firm focused on life science and medtech, dedicated to transforming innovative research into medical breakthroughs for global health.
RECORDATI
An international pharmaceutical group with a century of experience in research and development, maintaining a strong portfolio in rare disease treatments and specialty therapeutics.
What's next for STRM.BIO?
With the recent influx of capital, STRM.BIO is expected to prioritize the expansion of its pre-clinical pipeline and the optimization of its manufacturing processes. The company's roadmap likely includes scaling its EV production capabilities to meet the rigorous demands of upcoming regulatory filings and potential human clinical trials. Furthermore, the strategic involvement of its investor syndicate suggests a focus on long-term value creation through potential pharmaceutical partnerships and the continued validation of its platform's versatility across various therapeutic indications. As the firm matures, the focus will shift toward demonstrating the durability and precision of its delivery technology in vivo, a critical milestone for securing future growth and establishing a sustainable competitive advantage in the global gene therapy market.
See full STRM.BIO company page
